Study Summary
This trial will test the safety of a new drug, SAR440894, given to healthy adults aged 18-45 in ascending doses. There will be five cohorts of 8 subjects each, 6 receiving the drug and 2 receiving placebo, and 2 sentinel subjects who will be dosed first. The trial will last approximately 150 days.
- Chikungunya
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
5 Primary · 3 Secondary · Reporting Duration: Day 1 through Day 150
Trial Safety
Phase-Based Safety
Trial Design
5 Treatment Groups
Cohort 5
1 of 5
Cohort 4
1 of 5
Cohort 1
1 of 5
Cohort 2
1 of 5
Cohort 3
1 of 5
Experimental Treatment
40 Total Participants · 5 Treatment Groups
Primary Treatment: SAR440894 · Has Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 45 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Oklahoma | 100.0% |
What portion of applicants met pre-screening criteria?
Did not meet criteria | 100.0% |
Frequently Asked Questions
Is this clinical experiment actively welcoming participants?
"Yes, the latest information on clinicaltrials.gov confirms that this investigation is currently seeking volunteers for research. The study was first advertised on October 14th 2020 and has since been revised as of November 23rd 2022. 40 individuals are expected to be recruited from two distinct medical facilities." - Anonymous Online Contributor
Has SAR440894 obtained governmental sanctioning from the FDA?
"Owing to the fact that this is an early phase study, our experts at Power judged SAR440894's safety as a 1 on their scale. This conclusion was made due to insufficient data regarding both efficacy and security levels." - Anonymous Online Contributor
What is the aggregate population of participants for this research?
"Affirmative. Clinicaltrials.gov displays that this clinical trial, which was initially announced on October 14th 2020, is actively recruiting participants. The recruitment process requires 40 patients from 2 different medical centres." - Anonymous Online Contributor
Is the age eligibility for this trial limited to individuals under 20 years of age?
"Participants fitting the specified age range of 18 to 45 are eligible for this trial, while 3 other trials cater respectively to minors and those 65 years old or older." - Anonymous Online Contributor
What criteria must potential participants fulfill to join this trial?
"Those hoping to be selected for this study must have a diagnosis of chikungunya virus and fall between the age parameters of 18-45. The total number of participants being recruited is 40 individuals." - Anonymous Online Contributor